Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- The team shrank two years in a row.
- Figures corrected afterwards (2025).
Revenue
€ 0
▼ 100% vs 2024
Profit
Caution€ -2 million
▲ 21% vs 2024
Debts
Low€ 2.6 million
▲ 9% vs 2024
INTRESSA VASCULAR from Gembloux, company number BE0462587258, closed financial year 2025 with a result of € -2 million after tax. For that financial year INTRESSA VASCULAR recorded revenue of € 0 and equity of € 11.8 million. Compared with financial year 2024, the result moved from € -2.6 million to € -2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
What happened at INTRESSA VASCULAR?
What happened at INTRESSA VASCULAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Chong Wang stepped down as director. NBB
- Bellerive & Co Management stepped down as director. NBB
- ODMC BV stepped down as director. NBB
- Noshaq Partners SCRL stepped down as director. NBB
- Pierre Douette stepped down as director. NBB
- Pierre Lefebvre stepped down as director. NBB
- DG International Consulting SRL stepped down as director. NBB
- Corrected annual accounts filed for financial year 2025. Source: NBB ↗
In short
From € 3.8 million profit in 2021 to € 2 million loss in 2025.
Paid € 1,678 in corporate taxes since 2021.
Best year ever: 2021, with € 3.8 million profit.
On average € 32,400 of value added per employee in 2025.
A new publication or filing at INTRESSA VASCULAR? We notify you, reason included.
Follow INTRESSA VASCULARNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 25% of Shanghai Kaiyitong Medical Technology CO., LTD itself.
Directors
According to the 2025 annual accounts
Chairman of the board · represented by Philippe Felten
since 2024 · until 2027
Director · represented by Olivier DELPORTE
Also active at: Miracor Medical, ENDO TOOLS THERAPEUTICS, Samantree Medical
since 2021 · until 2027
Chong Wang
Director
since 2022 · until 2028
Director · represented by Eric BRANDT
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2021 · until 2027
DG International Consulting SRL
Director · represented by Denis GESTIN
Also active at: SYNERGIA MEDICAL, ENDO TOOLS THERAPEUTICS
since 2023 · until 2026
since 2021 · until 2027
Pierre Lefebvre
Director
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Rue Jules Poskin,Isnes 3
5032 Gembloux
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Details
- Company number
- 0462.587.258
- VAT number
- BE 0462.587.258
- Registered office
- Rue Jules Poskin,Isnes 3, 5032 Gembloux
- Names & denominations
- INTRESSA VASCULAR · CARDIATIS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 4 February 1998
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied